Skip to contentT
TScan Therapeutics, Inc.
T
TCRXTScan Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$1.05M$1.05M−65.8% vs Q2 2025 Net Income-$30.36M-$30.36MN/M vs Q2 2025 EPS Diluted-$0.23-$0.23N/M vs Q2 2025 Operating Income-$30,493,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$28,028,000N/M Margins · derivedOperating margin-2901.3%−1644.7 pt vs Q2 2025
Net margin-2888.6%−1687.3 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 12, 2026 · 43 d after period end